UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Fariborz (Fred) Mortazavi, M.D.

Specialty:

Hematology/Oncology

General Information:

Gender:	Male
Language(s):	English and Farsi

Affiliation(s):

Assistant Professor in Residence, Department of Medicine

Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

West Los Angeles Veterans Affairs Medical Center

Education:

Fellowship:	University of Illinois at Chicago, 2003 - 2006
Research Fellowship:	Memorial Sloan Kettering Cancer Center, 2002 - 2003
Residency:	St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, 2000-2002
Internship:	Mt. Sinai Medical Center, 1999-2000
Medical Degree:	M.D., Tehran University of Medical Sciences, Tehran, Iran, 1994

Certification(s):

Medical Board Certification(s):	Medical Oncology, American Board of Internal Medicine, 2006 Hematology, American Board of Internal Medicine, 2006 Internal Medicine, American Board of Internal Medicine, 2002

Contact Information:

Phone:	(310) 268-4567
Email:	fredmortazavi@ucla.edu

Practice Information:

Clinical Interest(s):	Thoracic malignancies

Scientific Interest(s):

Studying the signaling pathways that promote invasion and metastasis in lung cancer is currently the focus of Dr. Fred Mortazavi's research. For example, as part of the adherens junction, p120-catenin (p120ctn) plays an important role in the stability of cell-cell adhesions and downregulation of the p120-catenin is reported in a large proportion (60-80%) of non-small cell lung cancer (NSCLC) cases. Mortazavi and others reported that p120-catenin is transcriptionally downregulated in NSCLC and identified two signaling pathways that mediate p120-catenin repression. Identifying the prometastatic signaling events in cancer cells could pave the way for the future interventions in order to stop the metastatic process.

Selected Cancer-Related Publications:

Mortazavi F, Dubinett S, Rettig M. c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells. Clin Exp Metastasis. 2011 Apr;28(4):391-404. Epub 2011 Feb 20.

Mortazavi F, An J, Dubinett S, Rettig M. p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells. Mol Cancer Res. 2010 May;8(5):762-74. Epub 2010 May 11.